Asprosin in Breast Cancer

To evaluate the clinical utility of Asprosin measurement in breast cancer patients in comparison with healthy controls and patients with benign breast lesions.

To compare between Asprosin and the routine markers (CEA, CA15-3) as biomarkers for breast cancer diagnosis

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Females aged (40 ± 20 years) who did not receive any chemotherapy or surgical treatment and they will be divided as follow:

Group 1: healthy controls from healthy volunteers. Group 2: patients with benign breast lesions. Group 3: breast cancer patients.

Exclusion criteria

1- Female patients with any other type of malignant or benign tumors. 2- Past history of chemotherapy or surgical treatment of cancer.

Treatment and study plan

ELISA

Device

Specific test: Assay of asprosin marker will be measured by enzyme-linked immunosorbent assay ( ELISA).

Primary outcomes

Diagnostic value of Asprosin as a biomarker in breast cancer

Time frame: Baseline

Evaluation of the clinical utility of measurement of asprosin as a non invasive biomarker in the diagnosis of breast cancer

Secondary outcomes

Diagnostic value of Asprosin as a biomarker in breast cancer

Time frame: Baseline

Comparing asproin and the routine markers (CEA, CA15-3) as biomarkers for diagnosis of breast cancer.

Study contacts

Contact information is provided by the study sponsor or research team.

Eman Mohamed Abdelrahman

CONTACT

Marina Hanna Thabet

CONTACT

[email protected]

01007970949

Sponsors and collaborators

Lead sponsor

Marina Hanna Thabet Ghobrial

Other

Registry information

Official study title

Diagnostic Value of Asprosin As a Biomarker in Breast Cancer

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2025
First posted: Sep 19, 2024
Registry last updated: Sep 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting